Dror Ortho-design, INC 10-Q quarterly reports

Dror Ortho-Design reports continued development of its orthodontic platform, with reduced R&D spending, but faces significant going concern doubts due to ongoing losses and reliance on financing.

Dror Ortho-Design reports significant operating losses and a dwindling cash balance, raising substantial doubt about its ability to continue as a going concern, while also delaying its FDA submission for its novel orthodontic platform.

Pre-revenue aligner developer narrowed its quarterly loss, ended Q3 with $0.24M cash, and entered a $600k 0%-interest debenture financing in November with potential warrant coverage upon a future public offering.

Dror Ortho-Design, an orthodontic R&D company, reported a reduced net loss but faces substantial doubt about its ability to continue as a going concern due to ongoing losses and reliance on external financing.

Dror Ortho-Design, Inc. announced its Q1 2025 financial results, highlighting ongoing research and development of its orthodontic alignment platform and the necessity for additional funding to sustain operations.

Dror Ortho-Design reported increased research and development expenses and a net loss for the third quarter of 2024, alongside a significant increase in share-based compensation expenses.

Dror Ortho-Design reported increased research and development expenses and a net loss for the second quarter of 2024, as it continues to develop its orthodontic alignment platform.

Dror Ortho-Design reported a net loss of $1.3 million for the first quarter of 2024, driven by increased operating expenses, particularly in share-based compensation.